{"nctId":"NCT00248612","briefTitle":"Psychosocial and Medication Treatment for Anxiety in Alcoholism","startDateStruct":{"date":"2003-09","type":"ACTUAL"},"conditions":["Alcohol-Related Disorders","Anxiety Disorders"],"count":162,"armGroups":[{"label":"Venlafaxine & CBT","type":"EXPERIMENTAL","interventionNames":["Drug: Venlafaxine","Behavioral: CBT"]},{"label":"Placebo & CBT","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: CBT","Other: Placebo medication"]},{"label":"Venlafaxine & PMR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Venlafaxine","Other: Progressive muscle relaxation therapy (PMR)"]},{"label":"Placebo & PMR","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Progressive muscle relaxation therapy (PMR)","Other: Placebo medication"]}],"interventions":[{"name":"Venlafaxine","otherNames":["Effexor XR"]},{"name":"CBT","otherNames":[]},{"name":"Progressive muscle relaxation therapy (PMR)","otherNames":[]},{"name":"Placebo medication","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must be English-speaking males or females\n* Participants must be between 18 and 65 years old\n* Meet criteria for DSM-IV diagnosis of alcohol abuse or dependence\n* Meet criteria for Panic disorder, Social Phobia or Generalized Anxiety Disorder\n* Physically able to attend sessions at the Counseling Center\n* Able to read and write\n* Able to complete the structured interview and self-report assessment packet\n* Able to attend all treatment sessions and follow-up assessments\n* Able to sign a witnessed informed consent form\n* Participants express a desire to completely stop drinking alcohol or reduce alcohol consumption with the possible long-term goal of abstinence\n\nExclusion Criteria:\n\n* Meet DSM-IV diagnostic criteria for bipolar disorder, schizophrenia, bulimia/anorexia, or dementia\n* Currently taking anti-craving agents (e.g. Naltrexone, methadone)\n* Currently taking medication that has clinically significant interactions with venlafaxine\n* Previous use of venlafaxine\n* Currently taking other antidepressant medications\n* Currently taking medication known to decrease anxiety or alcohol consumption (e.g. antabuse)\n* Currently prescribed medications with known abuse potential (e.g., subjects on opioid agonist therapy)\n* Currently prescribed medications as a sleep aid (e.g. Ambien)\n* Currently taking herbal supplements that have been shown to interact with venlafaxine or affect anxiety symptoms\n* Currently pregnant, breastfeeding, plans of becoming pregnant during the course of the study, or not using medically acceptable form of birth control (oral contraceptives, barrier \\[diaphragm or condom\\] with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection).\n* Planning to relocate out-of-state within four months of protocol initiation\n* History of psychotic symptoms within the past 30 days\n* Experiencing severe symptoms of depression or have engaged in suicidal behaviors within the past 30 days\n* Medical contraindications to the use of venlafaxine \\[severe renal disease, cirrhosis, uncontrolled blood pressure, recent cardiovascular problems (e.g., heart attack), and seizure disorders; currently taking a monoamine oxidase inhibitor, MAOI\\]\n* Self-reported anxiety less than 15 on the Hamilton Rating Scale for Anxiety\n* Participant is a member of the same household of another subject already participating in the study\n* Participant is legally mandated (e.g., to avoid incarceration, monetary or other penalties, etc.) to participate in an alcohol treatment program\n* Participant has a current or recent (past 30 days) DSM-IV diagnosis of other substance abuse or dependence, with the exception of nicotine, marijuana, and caffeine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Global Impression Scale-I (CGI-I)","description":"Global improvement of alcohol dependence: Rate the total improvement in the participant's alcohol dependence symptoms whether or not, in your judgment, it is due entirely to treatment. Compared to his/her admission to the project, how much has s/he changed?\n\n(1-Not assessed, first rating, 2-Very much improved, 3-Much improved, 4-Minimally improved, 5-Unchanged, 6-Minimally worse, 7-Much worse, 8-Very much worse)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":"1.34"},{"groupId":"OG001","value":"3.81","spread":"1.21"},{"groupId":"OG002","value":"3.86","spread":"1.10"},{"groupId":"OG003","value":"4.05","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","spread":"1.38"},{"groupId":"OG001","value":"3.13","spread":"0.89"},{"groupId":"OG002","value":"3.50","spread":"1.09"},{"groupId":"OG003","value":"3.53","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"1.30"},{"groupId":"OG001","value":"2.61","spread":"0.78"},{"groupId":"OG002","value":"3.00","spread":"1.15"},{"groupId":"OG003","value":"2.92","spread":"0.95"}]}]}]},{"type":"PRIMARY","title":"Clinical Global Impression Scale-S (CGI-S)","description":"Global severity of alcohol dependence: Considering your total clinical experience with the alcohol dependent population how severe are his/her alcohol dependence symptoms at this time?\n\n(1-Normal, no symptoms, 2-Borderline symptoms, 3-Mild symptoms, 4-Moderate symptoms, 5-Marked symptoms, 6-Severe symptoms, 7-Among the most extreme symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"1.24"},{"groupId":"OG001","value":"3.76","spread":"0.89"},{"groupId":"OG002","value":"3.93","spread":"0.92"},{"groupId":"OG003","value":"4.18","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":"1.49"},{"groupId":"OG001","value":"2.88","spread":"1.26"},{"groupId":"OG002","value":"3.25","spread":"1.42"},{"groupId":"OG003","value":"3.40","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"1.88"},{"groupId":"OG001","value":"2.53","spread":"1.18"},{"groupId":"OG002","value":"2.60","spread":"1.51"},{"groupId":"OG003","value":"2.85","spread":"1.34"}]}]}]},{"type":"PRIMARY","title":"Craving Desire Scale (CDS)","description":"The Craving Desire Scale (CDS) is a 3-item scale (\"1. I do want to drink now\", \"2. I crave a drink right now\", 3. \"I have a desire for a drink right now\") used to identify the degree of current alcohol craving, with responses provided on a Likert scale of 1-7: with 1 meaning strongly disagree, and 7 meaning strongly agree to each of the 3 items. Total scores can range from 3 to 21 with higher scores indicating greater craving for alcohol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.63","spread":"6.03"},{"groupId":"OG001","value":"8.14","spread":"5.02"},{"groupId":"OG002","value":"8.21","spread":"5.94"},{"groupId":"OG003","value":"7.55","spread":"5.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.44","spread":"5.28"},{"groupId":"OG001","value":"7.41","spread":"5.06"},{"groupId":"OG002","value":"4.45","spread":"1.75"},{"groupId":"OG003","value":"5.56","spread":"3.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.38","spread":"1.94"},{"groupId":"OG001","value":"6.11","spread":"4.76"},{"groupId":"OG002","value":"5.10","spread":"2.08"},{"groupId":"OG003","value":"4.25","spread":"2.70"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Abstinent","description":"Abstaining from the consumption of intoxicating beverages.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Completion","description":"The number and percent of participants that completed the treatment in each arm of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Medication Compliance Rates","description":"The medication compliance rate is the percentage of participants in each study arm who took their medication based on pill counts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.89","spread":null},{"groupId":"OG001","value":"97.06","spread":null},{"groupId":"OG002","value":"88.70","spread":null},{"groupId":"OG003","value":"95.39","spread":null}]}]}]},{"type":"SECONDARY","title":"DASS Stress Subscale Score","description":"DASS (Depression Anxiety Stress Scales) assesses depression, anxiety and stress responses. Each of the three DASS scales contains 14 items, divided into subscales of 2-5 items with similar content. The stress subscale was used which assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Stress scores can range form 0-56 with 0-14=normal, 15-18=mild, 19-25=moderate, 26-33=severe. and 34+=extremely severe stress.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"7.6"},{"groupId":"OG001","value":"19.2","spread":"9.1"},{"groupId":"OG002","value":"21.5","spread":"11.3"},{"groupId":"OG003","value":"16.6","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"4.6"},{"groupId":"OG001","value":"9.6","spread":"7.9"},{"groupId":"OG002","value":"4.1","spread":"7.9"},{"groupId":"OG003","value":"11.2","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"HAM-A Scale","description":"The Hamilton Anxiety Rating Scale (HAM-A) is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety. The HAM-A probes 14 parameters each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. total scores can range from 0 to 56.where \\<17 indicates mild anxiety, 18-24 moderate anxiety and 25-30 severe anxiety. Higher scores reflect more anxiety.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"5.9"},{"groupId":"OG001","value":"14.2","spread":"7.3"},{"groupId":"OG002","value":"16.5","spread":"6.8"},{"groupId":"OG003","value":"12.9","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"6.9"},{"groupId":"OG001","value":"9.1","spread":"5.5"},{"groupId":"OG002","value":"7.9","spread":"5.5"},{"groupId":"OG003","value":"9.1","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"HAM-D Scale","description":"HAM-D (Hamilton Rating Scale for Depression) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The scoring is based on 17 items. Eight of the items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored on a 3 point scale from 0-2 where 0=none or absent and 2= severe. The total scores for the HAM-D can range from 0 to 50. The total scores are interpreted as: 0-7=normal, 8-13=mild, 14-18= moderate, 19-22= severe, and 23+=very severe depression. The higher the score the more severe the participant's depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":"5.7"},{"groupId":"OG001","value":"11.7","spread":"6.0"},{"groupId":"OG002","value":"13.0","spread":"7.2"},{"groupId":"OG003","value":"13.6","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"6.6"},{"groupId":"OG001","value":"8.5","spread":"4.6"},{"groupId":"OG002","value":"5.9","spread":"5.6"},{"groupId":"OG003","value":"10","spread":"6.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":24},"commonTop":[]}}}